Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society

Author's Avatar
Jun 13, 2023

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that multiple abstracts featuring data on the Company’s lead investigational therapy for the treatment of thyroid eye disease (TED) will be presented at the Annual Meeting of the Endocrine Society (ENDO 2023) to be held June 15-18, 2023, in Chicago, Illinois.